Dr. William E. Sanchez, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 43
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME86153
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Floridian Health Centers, LLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 43
- Services billed
- 93
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | 829 | 27 |
| Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | 25 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Hialeah, FL | 417 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Hialeah, FL | 401 |
| Gabapentin Other prescribers in Hialeah, FL | 213 |
| Atorvastatin Calcium Other prescribers in Hialeah, FL | 205 |
| Metformin Hcl Other prescribers in Hialeah, FL | 151 |
| Omeprazole Other prescribers in Hialeah, FL | 129 |
| Meclizine Hcl Other prescribers in Hialeah, FL | 123 |
| Losartan Potassium Other prescribers in Hialeah, FL | 121 |
| Lisinopril Other prescribers in Hialeah, FL | 109 |
| Folic Acid Other prescribers in Hialeah, FL | 80 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 12 companies. The companies reported $4,319,310 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants with Normal Renal Function and Participants with Various Degrees of Renal Im…
Amgen Inc. - A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Eli Lilly and Company · Completed · NCT05395481 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ModernaTX, Inc. · Terminated · NCT05701800 - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fib…
AstraZeneca Pharmaceuticals LP - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A dose-finding, double-blind, placebo-controlled phase 2 study to eva
GlaxoSmithKline, LLC. - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT05330975
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.